Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report

Author:

Reutter Theresa1,Fassunke Jana2ORCID,Püsken Michael3ORCID,Weber Jan-Phillip1,Binot Elke2,Eisert Anna1,Fischer Rieke1ORCID,Nogova Lucia1ORCID,Riedel Richard1,Schaufler Diana1,Scharpenseel Heather1,Scheffler Matthias1ORCID,Schulz Holger4,Waldschmidt Dirk‐Thomas5,Zander Thomas1ORCID,Merkelbach-Bruse Sabine2,Schirmacher Peter6,Büttner Reinhard2ORCID,Wolf Jürgen1ORCID,Michels Sebastian1ORCID

Affiliation:

1. Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne, University of Cologne, Cologne, Germany

2. Department of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

3. Faculty of Medicine and University Hospital Cologne, Institute for Diagnostic and Interventional Radiology, University of Cologne, Cologne, Germany

4. Practice for Clinical Hematology and Oncology, Frechen, Germany

5. Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

6. Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3